TheFlyOnTheWall.com repored this morning that Gilead Sciences, Inc. (NASDAQ:GILD), announced that the company has submitted a New Drug Application to Japan’s Pharmaceutical and Medical Devices Agency for approval of sofosbuvir, a once-daily nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C virus infection.
Gilead Sciences, Inc.(NASDAQ:GILD) opened trading today at $82.18 and is trading in the range of 82.18-82.22 thus far today. Gilead’s current valuation stands at $126.36 billion. Sector Performance Compared to other peers in the Biotechnology sector, GILD has outperformed in terms of quarterly revenue growth year over year at 0.98 vs. the industry average of 0.09. Gileads’s earnings per share is currently at 2.70, which trumps the sector average of -0.24.
Gilead Sciences is currently covered by 23 Wall Street analysts. The mean target price is $100.87 according to First Call. This presents a solid upside to the current price of the equity. The Mean Recommendation sits at 1.8 which is based on 10 Strong Buy, 13 Buy and 4 Hold ratings. The most recent analyst actions consisted of Robert W. Baird upgrading their rating from neutral to outperform in February. The current quarter EPS consensus estimate is 1.60 with revenue estimates of 5.30B. Sales are expected to grow at a 98.80% rate. Gilead reported actual earnings last quarter of 0.50 which meat the .50 consensus estimate.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of life threatening diseases in North America, South America, Europe, and the Asia-Pacific. The companys products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Sovaldi, Viread, and Hepsera products for the treatment of liver disease. It also offers Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; Vistide, an antiviral injection for the treatment of cytomegalovirus retinitis in adult patients with AIDS; and Macugen, an anti- angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages for the treatment of HIV, liver, oncology/inflammation, cardiovascular, and respiratory diseases. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with BMS, Janssen, and Japan Tobacco to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California.
- Forum verkenner
- Berichten: 35
- Lid geworden op: 05 okt 2012 12:57
- waarderingen: 22
Jaarlijkse omzetgroei v 97%, jaarlijkse winstgroei v 38%, P/E v 13.05 en zwaar ondergewaardeerd: dit zijn de aandelen die ik in mijn PF wil hebben
http://www.techinsider.net/gilead-scien ... 13851.html" onclick="window.open(this.href);return false;
http://www.fool.com/investing/general/2 ... cktai.aspx" onclick="window.open(this.href);return false;
Deelnemen aan het forum + meer functies?
Discussieer met duizenden beleggers, minder
advertenties, ideaal voor smartphone, betere
gebruikservaring en gratis abonneren op favoriete
onderwerpen. Registreer binnen enkele tellen